Intra-lesional ACE Inhibitor for Treatment of Keloid Scars
Status:
Not yet recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
Keloid scarring is a difficult and debilitating condition where one develops excessive
scarring after incision or laceration to the skin. Currently, there is no reliable treatment
of these scars. One of the more effective treatments available is serial intralesional
injection of a steroid after 90% excision of the keloid scar.
Angiotensin II is an active peptide in the body that results in vasoconstriction of the blood
vessels when activated. Medications used today like angiotensin II receptor blocks and
angiotensin converting enzyme inhibitors work to prevent the activation of angiotensin II and
are mainly used to help control blood pressure. Previous studies in rat models have shown
that angiotensin II receptor blockers can effectively reduce scar hypertrophy (a hallmark of
keloid scarring).
In this study, the investigators will conduct a randomized control trial, with one arm
receiving the standard therapy of 90% excision of the keloid scar with serial intra-lesional
injections of triamcinolone injection and the second arm receiving a combination of
triamcinolone + ACE-inhibitor. The outcome will be measured using the Patient and Observer
Scar Assessment Scale (POSAS), a validated assessment tool.